var data={"title":"Spontaneous intracerebral hemorrhage: Treatment and prognosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Spontaneous intracerebral hemorrhage: Treatment and prognosis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/contributors\" class=\"contributor contributor_credentials\">Guy Rordorf, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/contributors\" class=\"contributor contributor_credentials\">Colin McDonald, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/contributors\" class=\"contributor contributor_credentials\">Scott E Kasner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/contributors\" class=\"contributor contributor_credentials\">Janet L Wilterdink, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;May 21, 2014.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intracerebral hemorrhage (ICH) is the second most common cause of stroke, following ischemic stroke. Mortality and morbidity is high. Initial goals of treatment include preventing hemorrhage extension, as well as the prevention and management of elevated intracranial pressure along with other neurologic and medical complications.</p><p>The treatment and prognosis of spontaneous intracerebral hemorrhage will be reviewed here. Other aspects of ICH are discussed separately. (See <a href=\"topic.htm?path=spontaneous-intracerebral-hemorrhage-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">INITIAL TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Management of intracerebral hemorrhage (ICH) includes both medical and surgical interventions [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,2\" class=\"abstract_t\">1,2</a>]. </p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">General management issues</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Guidelines from the American Heart <span class=\"nowrap\">Association/American</span> Stroke Association <span class=\"nowrap\">(AHA/ASA)</span> recommend that patients with ICH receive monitoring and management in an intensive care unit [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,3\" class=\"abstract_t\">1,3</a>]. This recommendation is based upon the frequent association of ICH with elevations in intracranial pressure and blood pressure, the need for intubation and mechanical ventilation, and multiple medical issues and complications. Many neurologic as well as medical complications that require urgent intervention occur subsequent to the initial evaluation [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/4\" class=\"abstract_t\">4</a>]. Ideally, acute neurosurgical care should be available at the hospital in which patients are cared for [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/5\" class=\"abstract_t\">5</a>]. In addition, there is some evidence that intensive monitoring and stroke unit care is associated with improved outcomes in patients with acute stroke [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/6,7\" class=\"abstract_t\">6,7</a>]. </p><p>Early DNR orders or limitations to care are not always inappropriate after ICH; the difficulty lies in deciding when such limitations are indeed the most appropriate approach [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/8\" class=\"abstract_t\">8</a>]. Because prognostication for individual patients with acute ICH is an uncertain science, current guidelines suggest careful consideration of aggressive, full care during the first 24 hours after ICH onset and postponement of new DNR orders during that time [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,3\" class=\"abstract_t\">1,3</a>]. This recommendation does not apply to patients with preexisting DNR orders. (See <a href=\"#H8754524\" class=\"local\">'Prognosis'</a> below.) </p><p>Specific recommended interventions for patients with ICH include [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,9\" class=\"abstract_t\">1,9</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sources of fever should be treated, and current guidelines suggest the use of antipyretic medications to lower body temperature to normothermia in febrile patients with stroke [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,3\" class=\"abstract_t\">1,3</a>]. (See <a href=\"topic.htm?path=initial-assessment-and-management-of-acute-stroke#H12\" class=\"medical medical_review\">&quot;Initial assessment and management of acute stroke&quot;, section on 'Fever'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hyperglycemia in the first 24 hours after stroke is associated with adverse outcomes, and current guidelines suggest insulin treatment to target serum glucose level between 140 to 180 <span class=\"nowrap\">mg/dL</span> (&gt;7.8 to 10 <span class=\"nowrap\">mmol/L)</span> [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,3\" class=\"abstract_t\">1,3</a>]. Hypoglycemia should be avoided. (See <a href=\"topic.htm?path=initial-assessment-and-management-of-acute-stroke#H100191613\" class=\"medical medical_review\">&quot;Initial assessment and management of acute stroke&quot;, section on 'Hyperglycemia'</a> and <a href=\"topic.htm?path=initial-assessment-and-management-of-acute-stroke#H100191313\" class=\"medical medical_review\">&quot;Initial assessment and management of acute stroke&quot;, section on 'Hypoglycemia'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intermittent pneumatic compression is the mainstay for prevention of venous thromboembolism in patients with acute ICH. (See <a href=\"topic.htm?path=the-use-of-antithrombotic-therapy-in-patients-with-an-acute-or-prior-intracerebral-hemorrhage\" class=\"medical medical_review\">&quot;The use of antithrombotic therapy in patients with an acute or prior intracerebral hemorrhage&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Normal saline initially should be used for maintenance and replacement fluids; hypotonic fluids are contraindicated as they may exacerbate cerebral edema and intracranial pressure. Hypervolemia should be avoided as it may worsen cerebral edema [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/10\" class=\"abstract_t\">10</a>]. (See <a href=\"#H1113247210\" class=\"local\">'Intracranial pressure'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dysphagia is common and is a major risk factor for developing aspiration pneumonia. Prevention of aspiration in patients with acute stroke includes initial nulla per os (NPO) status until swallowing function is evaluated. Some experts suggest that patients with a GCS &lt;8 be intubated to decrease the risk of aspiration [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/10,11\" class=\"abstract_t\">10,11</a>]. (See <a href=\"topic.htm?path=medical-complications-of-stroke#H51492085\" class=\"medical medical_review\">&quot;Medical complications of stroke&quot;, section on 'Dysphagia and aspiration'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Reversal of anticoagulation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients who develop an ICH, all anticoagulant and antiplatelet drugs should be discontinued acutely after the onset of hemorrhage, and anticoagulant effect should be reversed immediately with appropriate agents [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,3\" class=\"abstract_t\">1,3</a>].</p><p>Aggressive use of intravenous <a href=\"topic.htm?path=vitamin-k-phytonadione-drug-information\" class=\"drug drug_general\">vitamin K</a>, unactivated prothrombin complex concentrate (also called factor IX complex), and other factors may be necessary in patients who suffer an ICH while taking <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a>. Reversal of anticoagulation in this setting is discussed in detail separately. (See <a href=\"topic.htm?path=reversal-of-anticoagulation-in-warfarin-associated-intracerebral-hemorrhage#H6\" class=\"medical medical_review\">&quot;Reversal of anticoagulation in warfarin-associated intracerebral hemorrhage&quot;, section on 'Reversal agents'</a>.)</p><p>Newer oral anticoagulants are increasing used as alternatives to <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> therapy. While there is less clinical experience with their reversal in the setting of ICH, a number of measures have been suggested to guide treatment in the setting of hemorrhagic complications. These are discussed separately. (See <a href=\"topic.htm?path=management-of-bleeding-in-patients-receiving-direct-oral-anticoagulants\" class=\"medical medical_review\">&quot;Management of bleeding in patients receiving direct oral anticoagulants&quot;</a>.)</p><p><a href=\"topic.htm?path=protamine-sulfate-drug-information\" class=\"drug drug_general\">Protamine sulfate</a> is recommended for urgent treatment of patients with heparin-associated ICH [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,3\" class=\"abstract_t\">1,3</a>]. Protamine sulfate can be administered by slow intravenous infusion (not greater than 20 <span class=\"nowrap\">mg/min</span> and no more than 50 mg over any 10-minute period). The appropriate dose of protamine sulfate is dependent upon the dose of heparin given and the time elapsed since that dose. (See <a href=\"topic.htm?path=heparin-and-lmw-heparin-dosing-and-adverse-effects\" class=\"medical medical_review\">&quot;Heparin and LMW heparin: Dosing and adverse effects&quot;</a>.)</p><p>Patients with severe coagulation factor deficiency or thrombocytopenia should receive appropriate factor replacement or platelet transfusion [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/3\" class=\"abstract_t\">3</a>]. </p><p>For patients on antiplatelet therapy, the limited available data suggests that platelet transfusions do not improve outcomes [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/12\" class=\"abstract_t\">12</a>]. (See <a href=\"topic.htm?path=clinical-and-laboratory-aspects-of-platelet-transfusion-therapy#H558384432\" class=\"medical medical_review\">&quot;Clinical and laboratory aspects of platelet transfusion therapy&quot;, section on 'Indications for platelet transfusion'</a>.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Blood pressure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The mean arterial pressure (MAP) is often elevated in patients with ICH. Management of hypertension is complicated by competing risks and potential benefits:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Severe elevations in blood pressure may worsen ICH by representing a continued force for bleeding, causing hemorrhage expansion and potentially worse outcomes [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/13,14\" class=\"abstract_t\">13,14</a>]. (See <a href=\"topic.htm?path=spontaneous-intracerebral-hemorrhage-pathogenesis-clinical-features-and-diagnosis#H6\" class=\"medical medical_review\">&quot;Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis&quot;, section on 'Hemorrhage enlargement'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>However, an increased MAP may be necessary to maintain cerebral perfusion in some patients, and lowering the arterial pressure (eg, to a systolic blood pressure [SBP] below 130 mmHg) may cause ischemia and worsen neurologic injury. Two observational studies have found that greater acute BP reductions are associated with increased incidence of areas of decreased diffusion on MRI scan [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/15-17\" class=\"abstract_t\">15-17</a>], however, other studies have not found that BP lowering affects regional CBF [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/18,19\" class=\"abstract_t\">18,19</a>], and the implication of these findings for prognosis is as yet undefined &#160; </p><p/><p>There are limited clinical trial data to inform decision making. Outcomes of death and severe disability were found to be similar among patients groups in the INTERACT2 trial, which randomly assigned 2839 patients with acute (within 6 hours) ICH and elevated blood pressure to either intensive blood pressure lowering (target systolic blood pressure (sBP) &lt;140 mm Hg within one hour) versus traditional management (target SBP &lt;180 mm Hg) [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/20\" class=\"abstract_t\">20</a>]. Intensive blood pressure lowering was associated with improved measures of disability according to modified Rankin scores, a secondary outcome measure. Adverse events were similar in the patient groups. The smaller INTERACT study and other nonrandomized studies have suggested that more aggressive BP lowering is associated with reduced hematoma growth [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,21-23\" class=\"abstract_t\">1,21-23</a>]. Another larger trial (ATACH II) is in progress [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/17\" class=\"abstract_t\">17</a>].</p><p class=\"headingAnchor\" id=\"H8751460\"><span class=\"h3\">Guidelines for treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Current guidelines for managing elevated blood pressure in acute spontaneous ICH are as follows [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,3\" class=\"abstract_t\">1,3</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with SBP &gt;200 mmHg or MAP &gt;150 mmHg, consider aggressive reduction of blood pressure with continuous intravenous infusion of medication accompanied by frequent (every five minutes) blood pressure monitoring</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with SBP &gt;180 mmHg or MAP &gt;130 mmHg and evidence or suspicion of elevated ICP, consider monitoring ICP and reducing blood pressure using intermittent or continuous intravenous medication to keep cerebral perfusion pressure in the range of 61 to 80 mmHg</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with SBP &gt;180 mmHg or MAP &gt;130 mmHg and <strong>no</strong> evidence or suspicion of elevated ICP, consider a modest reduction of blood pressure (eg, target MAP of 110 mmHg or target blood pressure of <span class=\"nowrap\">160/90</span> mmHg) using intermittent or continuous intravenous medication, and clinically reexamine the patient every 15 minutes</p><p/><p>These guidelines as well as the results of INTERACT2 also concluded that in patients presenting with a SBP of 150 to 200 mm Hg, acute lowering of SBP to 140 mm Hg is probably safe [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/3\" class=\"abstract_t\">3</a>]. <a href=\"topic.htm?path=labetalol-drug-information\" class=\"drug drug_general\">Labetalol</a>, <a href=\"topic.htm?path=nicardipine-drug-information\" class=\"drug drug_general\">nicardipine</a>, <a href=\"topic.htm?path=esmolol-drug-information\" class=\"drug drug_general\">esmolol</a>, <a href=\"topic.htm?path=enalapril-drug-information\" class=\"drug drug_general\">enalapril</a>, <a href=\"topic.htm?path=hydralazine-drug-information\" class=\"drug drug_general\">hydralazine</a>, <a href=\"topic.htm?path=nitroprusside-drug-information\" class=\"drug drug_general\">nitroprusside</a>, and <a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-drug-information\" class=\"drug drug_general\">nitroglycerin</a> are useful intravenous agents for controlling blood pressure [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Seizure prophylaxis and treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The reported risk of seizures in patients with acute spontaneous ICH ranges from 4.2 to 29 percent [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,10\" class=\"abstract_t\">1,10</a>]. Seizures are more common in lobar as compared to deep hemorrhage [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/24\" class=\"abstract_t\">24</a>]. The frequency depends in part on the extent of monitoring, as seizures associated with ICH are often nonconvulsive [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=spontaneous-intracerebral-hemorrhage-pathogenesis-clinical-features-and-diagnosis#H10\" class=\"medical medical_review\">&quot;Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis&quot;, section on 'Clinical presentation'</a> and <a href=\"topic.htm?path=nonconvulsive-status-epilepticus\" class=\"medical medical_review\">&quot;Nonconvulsive status epilepticus&quot;</a>.)</p><p>If a seizure occurs, appropriate intravenous antiepileptic drug (AED) treatment should be administered to prevent recurrent seizures [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/3\" class=\"abstract_t\">3</a>]. The choice of the initial antiepileptic agent depends upon individual circumstances and contraindications. Current guidelines suggest the use of intravenous <a href=\"topic.htm?path=fosphenytoin-drug-information\" class=\"drug drug_general\">fosphenytoin</a> or <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a> in this setting [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=initial-treatment-of-epilepsy-in-adults\" class=\"medical medical_review\">&quot;Initial treatment of epilepsy in adults&quot;</a> and <a href=\"topic.htm?path=convulsive-status-epilepticus-in-adults-classification-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis&quot;</a>.)</p><p>While some experts suggest a brief period of AED prophylaxis soon after ICH onset as a potential means of reducing the risk for early seizures in patients with lobar hemorrhages [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1\" class=\"abstract_t\">1</a>], 2010 guidelines recommend against prophylactic use of AEDs [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/3\" class=\"abstract_t\">3</a>] This strategy has not been tested prospectively in clinical trials. While two case series have found that prophylactic treatment with AEDs was associated with poorer outcomes (a concern that has also been raised for subarachnoid hemorrhage patients), these were nonrandomized, observational studies, and sample size did not allow for examination of a differential effect from different AEDs [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/25,26\" class=\"abstract_t\">25,26</a>]. </p><p class=\"headingAnchor\" id=\"H1113247210\"><span class=\"h2\">Intracranial pressure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Increased intracranial pressure (ICP) due to ICH can result from the hematoma itself and from surrounding edema, and may contribute to brain injury and neurologic deterioration. Current guidelines recommend a graded approach to the management of elevated ICP, beginning with simple measures that include the following [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1\" class=\"abstract_t\">1</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Elevate the head of the bed to 30 degrees, once hypovolemia is excluded.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Analgesia and sedation, particularly in unstable, intubated patients<br/><br/>Sedation should be titrated to control pain and minimize ICP elevation, while still permitting clinical evaluation of the patient's neurologic status [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1\" class=\"abstract_t\">1</a>]. Suggested intravenous agents for sedation are <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a>, or <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>. Suggested agents for analgesia and antitussive effect are <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> or <a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">alfentanil</a>. (See <a href=\"topic.htm?path=sedative-analgesic-medications-in-critically-ill-adults-selection-initiation-maintenance-and-withdrawal\" class=\"medical medical_review\">&quot;Sedative-analgesic medications in critically ill adults: Selection, initiation, maintenance, and withdrawal&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Normal saline initially should be used for maintenance and replacement fluids; hypotonic fluids are contraindicated. Mild hypernatremia should be tolerated. </p><p/><p>Glucocorticoids should NOT be used to lower the ICP in most patients with ICH. A randomized trial found that <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> did not improve outcome but did increase complication rates, primarily infection [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/27\" class=\"abstract_t\">27</a>].</p><p>Invasive monitoring and treatment of ICP should be considered for patients with GCS &lt;8 (<a href=\"image.htm?imageKey=NEURO%2F81854\" class=\"graphic graphic_table graphicRef81854 \">table 1</a>), those with clinical evidence of transtentorial herniation, or those with significant IVH or hydrocephalus [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/3\" class=\"abstract_t\">3</a>]. Measuring ICP directly allows directed treatment of ICP and blood pressure with a goal of maintaining a cerebral perfusion pressure (CPP) of 50 to 70 mmHg. More aggressive therapies for reducing elevated ICP include osmotic diuretics (eg, <a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">mannitol</a> and hypertonic saline solution), ventricular catheter drainage of cerebrospinal fluid, and neuromuscular blockade [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,3\" class=\"abstract_t\">1,3</a>]. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intravenous <a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">mannitol</a> is the treatment of choice to lower increased intracranial pressure, quickly and effectively lowering ICP [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/28\" class=\"abstract_t\">28</a>]. It is administered as an initial bolus of 1 <span class=\"nowrap\">g/kg,</span> followed by infusions of 0.25 to 0.5 <span class=\"nowrap\">g/kg</span> every six hours. The goal of therapy is to achieve plasma hyperosmolality (300 to 310 <span class=\"nowrap\">mosmol/kg)</span> while maintaining an adequate plasma volume; major side effects include hypovolemia and a hyperosmotic state [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=evaluation-and-management-of-elevated-intracranial-pressure-in-adults#H267641463\" class=\"medical medical_review\">&quot;Evaluation and management of elevated intracranial pressure in adults&quot;, section on 'Osmotic therapy and diuresis'</a>.) <br/><br/>Marked hyperosmolality should be avoided to prevent precipitation of acute renal failure [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/29\" class=\"abstract_t\">29</a>]. (See <a href=\"topic.htm?path=complications-of-mannitol-therapy\" class=\"medical medical_review\">&quot;Complications of mannitol therapy&quot;</a> and <a href=\"topic.htm?path=serum-osmolal-gap\" class=\"medical medical_review\">&quot;Serum osmolal gap&quot;</a>.) <br/></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Barbiturate anesthesia can be used if <a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">mannitol</a> fails to lower ICP to an acceptable range. Barbiturate coma acts by reducing cerebral metabolism, which results in a lowering of cerebral blood flow and thus decreases ICP [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1\" class=\"abstract_t\">1</a>]. It is of variable benefit for the treatment of elevated ICP from a variety of causes and is associated with a high rate of severe side effects, especially arterial hypotension [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/30\" class=\"abstract_t\">30</a>]. Continuous electroencephalogram monitoring is suggested during high-dose barbiturate treatment, with the dose titrated to a burst-suppression pattern of electrical activity [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=evaluation-and-management-of-elevated-intracranial-pressure-in-adults#H35\" class=\"medical medical_review\">&quot;Evaluation and management of elevated intracranial pressure in adults&quot;, section on 'Barbiturates'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hyperventilation to a PaCO2 of 25 to 30 mmHg causes dramatic and rapid lowering of ICP. However, the effect only lasts for minutes to a few hours. Thus, we reserve hyperventilation until the above therapies have been maximized [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/31\" class=\"abstract_t\">31</a>]. (See <a href=\"topic.htm?path=evaluation-and-management-of-elevated-intracranial-pressure-in-adults#H34\" class=\"medical medical_review\">&quot;Evaluation and management of elevated intracranial pressure in adults&quot;, section on 'Hyperventilation'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neuromuscular blockade is sometimes employed to reduce ICP in patients who are not responsive to analgesia and sedation alone, as muscle activity can contribute to increased ICP by raising intrathoracic pressure, thereby reducing cerebral venous outflow [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1\" class=\"abstract_t\">1</a>]. <br/><br/>Drawbacks of neuromuscular blockade include an increased risk of pneumonia and sepsis. In addition, the ability to evaluate the neurologic status is lost once the patient is paralyzed. (See <a href=\"topic.htm?path=clinical-use-of-neuromuscular-blocking-agents-in-critically-ill-patients\" class=\"medical medical_review\">&quot;Clinical use of neuromuscular blocking agents in critically ill patients&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cerebrospinal fluid drainage by intraventricular catheter placement (ventriculostomy) is an effective means of lowering ICP [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1\" class=\"abstract_t\">1</a>]. Ventriculostomy also allows direct monitoring of ICP. However, there are no prospective studies evaluating its effect on outcomes in patients with ICH. <br/><br/>Ventriculostomy is often used in the setting of obstructive hydrocephalus, which is a common complication of thalamic hemorrhage with third ventricle compression, and of cerebellar hemorrhage with fourth ventricle compression. Ventriculostomy is also frequently used in the setting of intraventricular hemorrhage with hydrocephalus. (See <a href=\"topic.htm?path=intraventricular-hemorrhage#H15\" class=\"medical medical_review\">&quot;Intraventricular hemorrhage&quot;, section on 'External ventricular drain'</a>.) </p><p/><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">Surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The indications for surgery in patients with ICH vary with the site of the bleed.</p><p class=\"headingAnchor\" id=\"H356881360\"><span class=\"h3\">Cerebellar hemorrhage</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Surgical removal of hemorrhage with cerebellar decompression should be performed for patients with cerebellar hemorrhages greater than 3 cm in diameter who are deteriorating, or who have brainstem compression <span class=\"nowrap\">and/or</span> hydrocephalus due to ventricular obstruction [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,3,32\" class=\"abstract_t\">1,3,32</a>]. Surgery decreases the risk of brainstem compression and obstructive hydrocephalus. External drainage alone, without posterior fossa decompression, may create the theoretical opportunity for upward herniation of the cerebellar mass and is not recommended.</p><p class=\"headingAnchor\" id=\"H356881366\"><span class=\"h3\">Supratentorial hemorrhage</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Surgical hematoma evacuation for supratentorial ICH is controversial; some patients may benefit, but indications for surgical treatment have not been conclusively defined [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,3,33-41\" class=\"abstract_t\">1,3,33-41</a>]. </p><p>We reserve surgical therapy for patients with life-threatening mass effect from supratentorial ICH, individualizing treatment decisions based on assessments of prognosis with and without surgical therapy. Current guidelines suggest consideration of standard craniotomy only for those who have lobar clots &gt;30 mL within 1 cm of the surface [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,3\" class=\"abstract_t\">1,3</a>]. No other patient group is recommended for surgery, and no surgical method other than standard craniotomy is supported. The routine evacuation of supratentorial ICH in the first 96 hours is not recommended.</p><p>Open craniotomy is the most widely studied surgical techniques in patients with supratentorial ICH [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1\" class=\"abstract_t\">1</a>]. Other methods include endoscopic hemorrhage aspiration, use of fibrinolytic therapy to dissolve the clot followed by aspiration, and CT-guided stereotactic aspiration. Studies of these less invasive techniques are in progress [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/42\" class=\"abstract_t\">42</a>].</p><p>A 2008 meta-analysis reviewed 10 randomized trials including 2059 patients [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/43\" class=\"abstract_t\">43</a>]. Surgery was associated with a reduced risk of death and dependency (OR 0.71; 95% CI 0.61 to 0.91). However, the benefit was not robust, and there was significant heterogeneity for death as an outcome. </p><p>The largest trial in the meta-analysis was the STICH trial. In this study, the 503 patients assigned to early (median time to surgery was 30 hours after hemorrhage onset) surgical hematoma evacuation were slightly more likely to have a favorable outcome at six months compared to those managed with initial conservative treatment, but the trend did not reach statistical significance [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/39\" class=\"abstract_t\">39</a>]. Benefit from those assigned to early surgery was nonsignificantly more likely in patients who had craniotomy as opposed to alternate techniques, and in those with hematoma located 1 cm or less from the cortical surface. The fact that 26 percent of patients initially assigned to conservative medical management underwent surgical evacuation may limit the ability of the study to show a benefit from surgery [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/40,44,45\" class=\"abstract_t\">40,44,45</a>].</p><p>Subsequently, the STITCH II trial found that rates of unfavorable outcomes at six months were similar in the 307 conscious patients treated with early (within 48 hours of onset) surgical hematoma evacuation versus the 294 patients treated conservatively (59 versus 62 percent) [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/46\" class=\"abstract_t\">46</a>]. Limitations in interpreting the results of this study include the selected nature of the patients treated, (conscious, without intraventricular extension), as well as a high crossover rate; 21 percent of patients assigned to conservative therapy did undergo surgery [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/47\" class=\"abstract_t\">47</a>].</p><p>When STITCH II data were combined with individual patient data from 14 other trials, a survival benefit for surgery was suggested for subgroups of patients, including those with poorer prognosis on presentation, those who deteriorated after presentation, and those with superficial ICH and no intraventricular extension [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/42,46\" class=\"abstract_t\">42,46</a>]. Further studies are required to conclusively determine which patients should receive surgical therapy.</p><p>Because of the questionable efficacy of surgery, it should only be considered as a life saving procedure to treat refractory increases in ICP; even in these instances, decisions should be addressed on a per patient basis:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Surgery should not be considered for patients who are either fully alert or deeply comatose. Patients with intermediate levels of arousal (obtundation-stupor) are more appropriate candidates.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Features that support performing surgery include a recent onset of hemorrhage, ongoing clinical deterioration, involvement of the nondominant hemisphere, and location of the hematoma near the cortical surface.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Features in favor of less aggressive therapy include serious concomitant medical problems, advanced age, stable clinical condition, remote onset of hemorrhage, involvement of the dominant hemisphere, and inaccessibility of the hemorrhage</p><p/><p class=\"headingAnchor\" id=\"H2514292\"><span class=\"h2\">Intraventricular hemorrhage</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with intraventricular extension of the ICH are at risk for hydrocephalus, especially if the third and fourth ventricles are involved. Such patients should be closely monitored. When neurologic deterioration occurs, an emergent CT scan should be done to exclude the development of hydrocephalus. Patients with neurologic deterioration in the setting of ventricular enlargement may be candidates for ventriculostomy and external ventricular drainage. </p><p>The management of intraventricular hemorrhage is discussed in detail separately. (See <a href=\"topic.htm?path=intraventricular-hemorrhage\" class=\"medical medical_review\">&quot;Intraventricular hemorrhage&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">Hemostatic therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>While hemostatic therapy offers the potential to improve outcomes by stopping ongoing hemorrhage and preventing hemorrhage enlargement, clinical trials have had mixed results. Current guidelines and systematic reviews have concluded that recombinant factor VIIa treatment for acute ICH that is not associated with <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> use is investigational and should not be used for treatment of ICH outside the context of a clinical trial [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,3,48\" class=\"abstract_t\">1,3,48</a>]. The use of factor VIIa for warfarin-associated ICH is discussed in detail separately. (See <a href=\"topic.htm?path=reversal-of-anticoagulation-in-warfarin-associated-intracerebral-hemorrhage\" class=\"medical medical_review\">&quot;Reversal of anticoagulation in warfarin-associated intracerebral hemorrhage&quot;</a>.)</p><p>The agent that has been most studied for use in ICH is activated recombinant factor VIIa (rFVIIa), which promotes hemostasis at sites of vascular injury [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/49\" class=\"abstract_t\">49</a>]. (See <a href=\"topic.htm?path=recombinant-factor-viia-clinical-uses-dosing-and-adverse-effects#H3\" class=\"medical medical_review\">&quot;Recombinant factor VIIa: Clinical uses, dosing, and adverse effects&quot;, section on 'Mechanism of action'</a>.)</p><p>While preliminary studies suggested that treatment with rFVIIa was safe and effective for ICH [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/50,51\" class=\"abstract_t\">50,51</a>], results from the multicenter double-blind phase 3 clinical trial showed no benefit for primary clinical outcomes [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/52\" class=\"abstract_t\">52</a>]. The trial randomly assigned 841 patients with spontaneous ICH to receive either rFVIIa (20 or 80 <span class=\"nowrap\">mcg/kg)</span> or placebo within four hours of symptom onset. Compared with placebo, treatment with rFVIIa was associated with a significant reduction in hematoma growth but did not result in improvement in the primary outcome measures, death or severe disability at day 90. In contrast, the earlier multicenter phase 2B study evaluated 399 patients with spontaneous ICH and found that treatment significantly reduced the risk of severe disability or death compared with placebo at 90 days (absolute risk reduction of 16 percent) [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/51\" class=\"abstract_t\">51</a>].</p><p>Recombinant factor VIIa has a potential risk of serious side effects from activation of the coagulation system or thrombosis [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/49\" class=\"abstract_t\">49</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the phase 3 trial, the overall frequency of thromboembolic serious adverse events was similar among treatment groups, but the rate of arterial thromboembolic serious adverse events (myocardial infarction or cerebral infarction) was significantly higher in the group assigned to 80 <span class=\"nowrap\">mcg/kg</span> when compared with placebo (8 versus 4 percent) [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/52\" class=\"abstract_t\">52</a>]. Similar findings were noted in an analysis of pooled data from three earlier randomized controlled trials of rFVIIa for spontaneous ICH, in which the rate of arterial thromboembolic serious adverse events was significantly increased in those assigned to high-dose rFVIIa (120 to 160 <span class=\"nowrap\">mcg/kg)</span> compared with placebo (5.4 versus 1.7 percent) [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/53\" class=\"abstract_t\">53</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Small open-label studies suggest that rFVIIa treatment for ICH is associated with increased rates of troponin elevation and myocardial infarction [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/54\" class=\"abstract_t\">54</a>] and higher than expected rates of posthemorrhagic hydrocephalus [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/55\" class=\"abstract_t\">55</a>]. (See <a href=\"topic.htm?path=recombinant-factor-viia-clinical-uses-dosing-and-adverse-effects#H25\" class=\"medical medical_review\">&quot;Recombinant factor VIIa: Clinical uses, dosing, and adverse effects&quot;, section on 'Safety issues'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H8751556\"><span class=\"h1\">SECONDARY TREATMENT ISSUES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Early mobilization and rehabilitation are suggested in patients with ICH who are clinically stable [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,3\" class=\"abstract_t\">1,3</a>].</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h2\">Resumption of antiplatelet therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Our experience with the use of <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> suggests that it is probably safe to resume therapy after the acute phase of ICH provided that blood pressure is well controlled and that the indication for antiplatelet treatment is sufficiently strong that the potential benefit outweighs the increase in risk of recurrent ICH. (See <a href=\"#H24\" class=\"local\">'Timing and dose'</a> below.)</p><p>There are limited data that specifically address this issue. Therefore, most decisions must be made by extrapolating from the limited data regarding antiplatelet therapy and the risk of primary ICH. Meta-analyses of randomized controlled trials suggest that <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> use is associated with an approximately 40 percent relative increase in the risk of initial ICH, which translates into a very small absolute increase in risk [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/56,57\" class=\"abstract_t\">56,57</a>]. In the setting of cerebral amyloid angiopathy, aspirin use may be associated with a greater risk of recurrent ICH [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/58\" class=\"abstract_t\">58</a>]. (See <a href=\"topic.htm?path=the-use-of-antithrombotic-therapy-in-patients-with-an-acute-or-prior-intracerebral-hemorrhage#H15\" class=\"medical medical_review\">&quot;The use of antithrombotic therapy in patients with an acute or prior intracerebral hemorrhage&quot;, section on 'Risk associated with antithrombotic therapy'</a> and <a href=\"topic.htm?path=cerebral-amyloid-angiopathy#H23\" class=\"medical medical_review\">&quot;Cerebral amyloid angiopathy&quot;, section on 'Avoiding anticoagulants and antiplatelet agents'</a>.)</p><p>Although <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> reduces the risk of ischemic stroke by 25 percent, this benefit is largely negated by the associated increased risk of recurrent ICH, which typically causes more disability than ischemic stroke. Therefore, we do not recommend aspirin or antiplatelets for those patients with only an &quot;average&quot; risk of recurrent ischemic stroke. What exactly constitutes &quot;average&quot; or &quot;above average&quot; risk is not certain, but we consider hypertension, diabetes, hypercholesterolemia, and the absence of heart disease to be markers of average risk. Atrial fibrillation, cardiomyopathy, large vessel extracranial and intracranial stenoses, and malignancy can be considered as markers for those with &quot;above average&quot; risk who may benefit from long-term antiplatelet therapy after ICH.</p><p>We also suggest not resuming <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> or antiplatelet therapy for primary prevention of cardiovascular disease. In the few existing primary prevention studies, patients with any prior ICH were excluded. Such patients should avoid aspirin unless a compelling indication for aspirin use develops later on.</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h3\">Timing and dose</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The timing of antiplatelet use after ICH is largely empiric. There is risk of rebleeding and hematoma expansion in the first several hours. At 10 days, rebleeding is unlikely. The <span class=\"nowrap\">AHA/ASA</span> guidelines of 2006 state that antiplatelets should be discontinued for at least one to two weeks [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/59\" class=\"abstract_t\">59</a>].</p><p>Some experts have argued that <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> can be used safely as soon as 48 hours after ICH in those who require prophylaxis for venous thromboembolism. We agree, provided neuroimaging has demonstrated a stable ICH. (See <a href=\"topic.htm?path=the-use-of-antithrombotic-therapy-in-patients-with-an-acute-or-prior-intracerebral-hemorrhage#H5\" class=\"medical medical_review\">&quot;The use of antithrombotic therapy in patients with an acute or prior intracerebral hemorrhage&quot;, section on 'Prevention'</a>.)</p><p>If <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> is used after ICH, we agree with others that a lower dose (30 to 160 mg daily) is both effective and safer than higher doses. (See <a href=\"topic.htm?path=the-use-of-antithrombotic-therapy-in-patients-with-an-acute-or-prior-intracerebral-hemorrhage\" class=\"medical medical_review\">&quot;The use of antithrombotic therapy in patients with an acute or prior intracerebral hemorrhage&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h2\">Resumption of anticoagulation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The question of when to restart anticoagulation in patients at high risk for embolic events who have suffered an ICH has not been definitively answered [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/60\" class=\"abstract_t\">60</a>]. For patients who require anticoagulation soon after a cerebral hemorrhage, the <span class=\"nowrap\">AHA/ASA</span> guidelines conclude that intravenous heparin may be safer than oral anticoagulation [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/60\" class=\"abstract_t\">60</a>]. In addition, the guidelines suggest that oral anticoagulants may be resumed three to four weeks after onset of the hemorrhage with rigorous monitoring and maintenance of INRs in the lower end of the therapeutic range. It is reasonable to consider risk factors for recurrent ICH when making <span class=\"nowrap\">risk/benefit</span> decisions regarding resumption of oral anticoagulation. (See <a href=\"#H8754607\" class=\"local\">'Recurrence'</a> below.)</p><p>Resumption of anticoagulation is discussed in greater detail separately. (See <a href=\"topic.htm?path=the-use-of-antithrombotic-therapy-in-patients-with-an-acute-or-prior-intracerebral-hemorrhage\" class=\"medical medical_review\">&quot;The use of antithrombotic therapy in patients with an acute or prior intracerebral hemorrhage&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H26\"><span class=\"h2\">Secondary prevention</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Efforts to control blood pressure over the long term are likely to significantly reduce the risk of recurrent ICH. Guidelines published in 2010 suggest a goal blood pressure of <span class=\"nowrap\">&lt;140/90</span> [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/3\" class=\"abstract_t\">3</a>]. In the PROGRESS trial, among over 6000 patients with prior cerebrovascular events and a mean baseline blood pressure of <span class=\"nowrap\">147/86,</span> a modest reduction in blood pressure of <span class=\"nowrap\">9/4</span> mmHg decreased the rate of ICH by 50 percent (95% CI 26%-67%) [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/61\" class=\"abstract_t\">61</a>]. In the subgroup of 611 patients with prior ICH, there was a similar 49 percent risk reduction (95% CI 18%-68%) for recurrent ICH. </p><p>While treating hypertension is the most important step to reduce the risk of ICH, and probably recurrent ICH, stopping smoking, heavy alcohol use, and cocaine use are also recommended [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,62\" class=\"abstract_t\">1,62</a>].</p><p>There are insufficient data to recommend general restrictions on the use of statin agents [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/3\" class=\"abstract_t\">3</a>]. While a number of studies have found an inverse relationship between total and LDL-cholesterol and the risk of ICH [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/63-71\" class=\"abstract_t\">63-71</a>], treatment with statins does not appear to increase the risk of primary ICH or to negatively impact prognosis according to a number of studies and meta-analyses [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/72-78\" class=\"abstract_t\">72-78</a>]. Given the conflicting data, it seems to be reasonable to weigh the benefits and possible risks of statin therapy in individual patients who are otherwise at risk for ICH recurrence [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/79-81\" class=\"abstract_t\">79-81</a>]. (See <a href=\"#H8754607\" class=\"local\">'Recurrence'</a> below.)</p><p class=\"headingAnchor\" id=\"H8754524\"><span class=\"h1\">PROGNOSIS</span></p><p class=\"headingAnchor\" id=\"H8754565\"><span class=\"h2\">Mortality and functional outcome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The 30-day mortality from ICH ranges from 35 to 52 percent [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/82-90\" class=\"abstract_t\">82-90</a>]; one-half of these deaths occur within the first two days [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/84,88,91\" class=\"abstract_t\">84,88,91</a>]. A systematic review estimated that between 12 and 39 percent of patients achieve independent function [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/89\" class=\"abstract_t\">89</a>].</p><p>The prognosis after ICH depends upon the location of hemorrhage (supra versus infratentorial location), size of the hematoma, level of consciousness, patient age, and overall medical health and condition [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1,84,85,87,90-93\" class=\"abstract_t\">1,84,85,87,90-93</a>]. In addition, preceding oral anticoagulation therapy, and possibly antiplatelet therapy, appears to be associated with worse outcomes after ICH [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/91,94\" class=\"abstract_t\">91,94</a>]. One study found that hemorrhage from a cerebral arteriovenous malformation were associated with a lower case-fatality rate, despite a similar hemorrhage volume and a higher admission Glasgow coma scale compared with spontaneous ICH [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/95\" class=\"abstract_t\">95</a>]. Other studies also suggest that hemorrhage due to vascular malformations is associated with lower mortality than other causes of ICH [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/96,97\" class=\"abstract_t\">96,97</a>].</p><p>Long-term survival after primary ICH also appears to be decreased compared with controls from the general population matched for age and sex [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/85,87,90,98,99\" class=\"abstract_t\">85,87,90,98,99</a>]. A retrospective cohort study identified 411 patients with first ever ICH and found that the annual risk of dying compared with controls was increased 4.5-fold during the first year after ICH and 2.2-fold during years two to six [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/85\" class=\"abstract_t\">85</a>]. A subsequent longitudinal prospective cohort study evaluated patients who had survived the first three months after ICH and observed that the mortality at seven years was significantly higher than controls (32.9 versus 19.4 percent) [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/98\" class=\"abstract_t\">98</a>]. In a population-based cohort of patients hospitalized after ICH in the Greater <span class=\"nowrap\">Cincinnati/Northern</span> Kentucky area, the ten-year survival was 18 percent [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/86\" class=\"abstract_t\">86</a>]. Major causes of mortality appear to be stroke and ischemic heart disease [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/99\" class=\"abstract_t\">99</a>].</p><p class=\"headingAnchor\" id=\"H8754571\"><span class=\"h2\">Risk factors for poor outcomes</span></p><p class=\"headingAnchor\" id=\"H8754577\"><span class=\"h3\">Initial ICH volume and level of consciousness</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The ICH volume on initial head CT scan and level of consciousness on admission may be particularly important prognostic indicators [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/84,97,100\" class=\"abstract_t\">84,97,100</a>]. This point is illustrated by a study of 188 patients with ICH that analyzed predictors of 30-day mortality [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/84\" class=\"abstract_t\">84</a>]; the following observations were made:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An ICH volume of 60 cm3 or greater on initial CT and a Glasgow coma scale score (<a href=\"image.htm?imageKey=NEURO%2F81854\" class=\"graphic graphic_table graphicRef81854 \">table 1</a>) of eight or less predicted a 30-day mortality of 91 percent.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An ICH volume less than 30 cm3 and a Glasgow coma scale score of nine or more predicted a 30-day mortality of 19 percent.</p><p/><p>The method for calculating ICH volume from head CT is discussed separately. (See <a href=\"topic.htm?path=spontaneous-intracerebral-hemorrhage-pathogenesis-clinical-features-and-diagnosis#H18\" class=\"medical medical_review\">&quot;Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis&quot;, section on 'Head CT'</a>.)</p><p>Other studies have also found that GCS is a useful predictor of outcome [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/101\" class=\"abstract_t\">101</a>].</p><p class=\"headingAnchor\" id=\"H8754583\"><span class=\"h3\">Hematoma growth and clinical deterioration</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hematoma growth</strong>, particularly within the first 24 hours, is also an independent predictor of mortality and poor outcome [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/102\" class=\"abstract_t\">102</a>]. In a meta-analysis of 218 patients with spontaneous ICH who had a head CT scan within three hours of onset and follow-up head CT within 24 hours, each 10 percent increase in ICH growth was associated with increased mortality (hazard ratio 1.05, 95% CI 1.03-1.08) and worse outcome as measured by the modified Rankin scale (odds ratio 0.84, 95% CI 0.75-0.92) [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/103\" class=\"abstract_t\">103</a>]. That is, for each 10 percent increase in hematoma volume, patients were 5 percent more likely to die and 16 percent more likely to increase one point on the modified Rankin scale (<a href=\"image.htm?imageKey=NEURO%2F75411\" class=\"graphic graphic_table graphicRef75411 \">table 2</a>). A subsequently published analysis found that while all measures of hematoma growth are robust predictors of worse outcomes, absolute increases in hemorrhage volume have higher predictive values compared with relative increases [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/104\" class=\"abstract_t\">104</a>]. <br/><br/>Risk factors for hematoma enlargement (contrast extravasation or &ldquo;spot sign&rdquo; on CTA, blood pressure, antithrombotic therapy) are also associated with worse outcomes and discussed separately. (See <a href=\"topic.htm?path=spontaneous-intracerebral-hemorrhage-pathogenesis-clinical-features-and-diagnosis#H6\" class=\"medical medical_review\">&quot;Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis&quot;, section on 'Hemorrhage enlargement'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Intraventricular and subarachnoid extension</strong> of ICH may be present on initial evaluation or occur subsequently. Data from a number of studies suggest that extension of blood into the ventricles <span class=\"nowrap\">and/or</span> subarachnoid space is an independent predictor of poor outcome in patients with spontaneous ICH [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/97,105-111\" class=\"abstract_t\">97,105-111</a>]. One of the largest of these reports evaluated 406 patients with ICH, 45 percent of whom had intraventricular extension of hemorrhage [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/109\" class=\"abstract_t\">109</a>]. After controlling for age and ICH volume, a poor outcome at discharge (defined as a modified Rankin scale score of 4 to 6 (<a href=\"image.htm?imageKey=NEURO%2F75411\" class=\"graphic graphic_table graphicRef75411 \">table 2</a>)) was significantly more likely in patients with intraventricular hemorrhage than in those without intraventricular hemorrhage (odds ratio 2.25, 95% CI 1.40-3.64). Intraventricular hemorrhage is discussed in detail separately. (See <a href=\"topic.htm?path=intraventricular-hemorrhage\" class=\"medical medical_review\">&quot;Intraventricular hemorrhage&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Early</strong> <strong>neurologic</strong> <strong>deterioration</strong> within 48 hours after ICH onset is not infrequent and is associated with a poor prognosis. Potential mechanisms include hemorrhage enlargement, development of hydrocephalus, and perilesional edema [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/102,112\" class=\"abstract_t\">102,112</a>]. The inflammatory response to the hemorrhage may also play a role.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In a cohort study of 266 patients with ICH admitted within 12 hours of stroke onset, early neurologic deterioration occurred in 61 (23 percent) and was associated with an eight-fold increase in the probability of a poor outcome (95% CI 2.7-25.5) [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/113\" class=\"abstract_t\">113</a>]. Independent predictors of early neurologic deterioration on admission included elevations in body temperature, neutrophil count, and serum fibrinogen level (odds ratios 24.5, 2.1, and 5.6, respectively), all of which could be interpreted as markers of an inflammatory response. Factors measured at 48 hours that were associated with early neurologic deterioration included ICH growth on repeat head CT, intraventricular bleeding, and high systolic blood pressure.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In many [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/91,112,114,115\" class=\"abstract_t\">91,112,114,115</a>] but not all [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/113\" class=\"abstract_t\">113</a>] reports, the initial ICH volume on CT is an independent predictor of early deterioration. The degree and subsequent expansion of perilesional edema is strongly related to the size of the initial ICH volume, and at least in one study, did not appear have an independent effect in predicting outcome [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/116\" class=\"abstract_t\">116</a>].</p><p/><p class=\"headingAnchor\" id=\"H8754589\"><span class=\"h3\">Preceding antithrombotic use</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the setting of an acute ICH, patients with preceding use of anticoagulants or antiplatelet agents appear to have larger initial hematoma volumes or greater hemorrhage enlargement leading to worse outcomes [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/117,118\" class=\"abstract_t\">117,118</a>]. However, the available evidence associating antithrombotic use with poor outcomes is mainly observational.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Oral anticoagulants</strong> &mdash; Patients on oral anticoagulant therapy have a mortality rate of 52 to 73 percent after ICH [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/94,117,119,120\" class=\"abstract_t\">94,117,119,120</a>]. In nonrandomized comparisons, these rates appear to be higher than those not on anticoagulation therapy with reported relative risks ranging from 3 to 4 [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/94,117\" class=\"abstract_t\">94,117</a>]. This increased risk may be mitigated, but not eliminated by rapid reversal of anticoagulation [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/121\" class=\"abstract_t\">121</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Antiplatelets</strong> &mdash; The evidence regarding preceding antiplatelet use with prognosis after ICH is not as clear, with some [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/94,118,122-124\" class=\"abstract_t\">94,118,122-124</a>] but not all [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/120,125-129\" class=\"abstract_t\">120,125-129</a>] studies reporting worse prognosis or greater hematoma enlargement with ICH. A systematic review of 25 cohort studies concluded that prior antiplatelet use was associated with increased mortality (OR = 1.3), but not poor functional outcome after ICH [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/130\" class=\"abstract_t\">130</a>].</p><p/><p class=\"headingAnchor\" id=\"H8754595\"><span class=\"h3\">ICH score</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A simple six-point clinical grading scale called the ICH score has been devised to predict mortality after ICH [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/131\" class=\"abstract_t\">131</a>]. This scale incorporates several clinical components that may be independent predictors of outcome.</p><p>The ICH score is determined by adding the score from each component as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Glasgow Coma Scale (GCS) score 3 to 4 (= 2 points); GCS 5 to 12 (= 1 point) and GCS 13 to 15 (= 0 points) (<a href=\"image.htm?imageKey=NEURO%2F81854\" class=\"graphic graphic_table graphicRef81854 \">table 1</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>ICH volume &ge;30 cm3 (= 1 point), ICH volume &lt;30 cm3 (= 0 points)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intraventricular extension of hemorrhage present (= 1 point); absent (= 0 points)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infratentorial origin yes (= 1 point); no (= 0 points)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Age &ge;80 (= 1 point); &lt;80 (= 0 points)</p><p/><p>Thirty-day mortality rates increased steadily with ICH score; mortality rates for ICH scores of 1, 2, 3, 4, and 5 were 13, 26, 72, 97, and 100 percent, respectively. No patient with an ICH score of 0 died, and none had a score of 6 in the cohort.</p><p>The ICH score has been validated by retrospective [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/132\" class=\"abstract_t\">132</a>] and prospective [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/133,134\" class=\"abstract_t\">133,134</a>] analysis. A modified ICH score [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/132\" class=\"abstract_t\">132</a>] using the National Institutes of Health Stroke Scale (NIHSS) score [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/135\" class=\"abstract_t\">135</a>] (<a href=\"image.htm?imageKey=NEURO%2F61698\" class=\"graphic graphic_table graphicRef61698 \">table 3</a>) in place of the GCS score may be a better predictor of good outcome than the original ICH score.</p><p class=\"headingAnchor\" id=\"H8754601\"><span class=\"h3\">Other factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patient age and overall medical health and condition have an important role in the patient&rsquo;s survival and morbidity after ICH [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/136\" class=\"abstract_t\">136</a>].</p><p>Accumulating data suggest that the early use of do not resuscitate (DNR) orders, along with decisions to limit aggressive treatments <span class=\"nowrap\">and/or</span> withdraw medical care may negatively influence outcome in patients with ICH, and may even invalidate some prognostic models that do not control for this variable [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/8,137-140\" class=\"abstract_t\">8,137-140</a>].</p><p>A number of reports have noted that elevated admission blood glucose after ICH is a poor prognostic indicator [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/9,85,91,141-144\" class=\"abstract_t\">9,85,91,141-144</a>]. However, it is unclear if elevated glucose directly contributes to poor outcome, or if it alternatively is present secondarily as part of the stress response to severe ICH. </p><p>Low total and LDL cholesterol have been linked to a risk of ICH. (See <a href=\"topic.htm?path=spontaneous-intracerebral-hemorrhage-pathogenesis-clinical-features-and-diagnosis#H8\" class=\"medical medical_review\">&quot;Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis&quot;, section on 'Risk factors'</a>.) In one study of 108 patients with ICH, lower serum LDL-cholesterol predicted early hematoma growth, neurologic deterioration, and three-month mortality [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/145\" class=\"abstract_t\">145</a>].</p><p>At least two studies have found that extensive white matter lesions on CT or MRI is associated with worse outcomes [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/146,147\" class=\"abstract_t\">146,147</a>]. Another study found that elevated C-reactive protein levels were an independent predictor of mortality after ICH [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/148\" class=\"abstract_t\">148</a>]. </p><p>A number of studies have found that a significant number of patients with ICH have acute ischemic lesions on diffusion-weighted MRI imaging that are not contiguous to the hematoma [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/15\" class=\"abstract_t\">15</a>]. The implication for these findings for prognosis are as yet undefined, although one study found that the presence of these lesions were associated with increased odds of death and disability [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/16\" class=\"abstract_t\">16</a>]. (See <a href=\"topic.htm?path=spontaneous-intracerebral-hemorrhage-pathogenesis-clinical-features-and-diagnosis#H5\" class=\"medical medical_review\">&quot;Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis&quot;, section on 'Mechanisms of brain injury'</a>.)</p><p class=\"headingAnchor\" id=\"H8754607\"><span class=\"h2\">Recurrence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recurrent hypertensive ICH occurs in as many as 5 percent of patients [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/88,149-151\" class=\"abstract_t\">88,149-151</a>]. Recurrence is most common within two years of the first hemorrhage [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/150\" class=\"abstract_t\">150</a>]. In one study with a three-year follow-up, the risk for subsequent cerebral infarction was similar to the risk of recurrent hemorrhage [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/88\" class=\"abstract_t\">88</a>].</p><p>Uncontrolled hypertension appears to be the most important risk factor for recurrent hemorrhage [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/149\" class=\"abstract_t\">149</a>]. Other risk factors variably identified as associated with recurrent ICH include [<a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/3,62,152\" class=\"abstract_t\">3,62,152</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Uncontrolled hypertension</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lobar location of initial ICH</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Older age</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Male gender</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ongoing anticoagulation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Apolipoprotein E epsilon 2 or epsilon 4 alleles</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Greater number of microbleeds on MRI</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ischemic stroke history</p><p/><p/><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=hemorrhagic-stroke-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Hemorrhagic stroke (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=hemorrhagic-stroke-treatment-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Hemorrhagic stroke treatment (Beyond the Basics)&quot;</a>)</p><p/><p/><p class=\"headingAnchor\" id=\"H28\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with acute ICH should be managed in an intensive care unit. General management issues include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Discontinuation of all anticoagulant and antiplatelet drugs, and immediate reversal of anticoagulant effects with the appropriate agents. (See <a href=\"topic.htm?path=reversal-of-anticoagulation-in-warfarin-associated-intracerebral-hemorrhage\" class=\"medical medical_review\">&quot;Reversal of anticoagulation in warfarin-associated intracerebral hemorrhage&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Maintenance of normothermia and evaluation and treatment of fever source. (See <a href=\"topic.htm?path=initial-assessment-and-management-of-acute-stroke#H12\" class=\"medical medical_review\">&quot;Initial assessment and management of acute stroke&quot;, section on 'Fever'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Normal saline initially should be used for maintenance and replacement fluids. (See <a href=\"#H14\" class=\"local\">'General management issues'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Treating hyperglycemia (elevated serum glucose &gt;185 <span class=\"nowrap\">mg/dL</span> (&gt;10.3 <span class=\"nowrap\">mmol/L)</span> with insulin; hypoglycemia should be avoided. (See <a href=\"topic.htm?path=initial-assessment-and-management-of-acute-stroke#H100191613\" class=\"medical medical_review\">&quot;Initial assessment and management of acute stroke&quot;, section on 'Hyperglycemia'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Prevention of aspiration in patients with acute stroke includes initial nulla per os (NPO) status until swallowing function is evaluated. (See <a href=\"topic.htm?path=initial-assessment-and-management-of-acute-stroke#H6\" class=\"medical medical_review\">&quot;Initial assessment and management of acute stroke&quot;, section on 'Swallowing assessment'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Current guidelines suggest consideration of aggressive full care during the first 24 hours after intracerebral hemorrhage (ICH) onset and postponement of new do not resuscitate (DNR) orders during that time. (See <a href=\"#H14\" class=\"local\">'General management issues'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Prevention of deep venous thrombosis and venous thromboembolism. (See <a href=\"topic.htm?path=the-use-of-antithrombotic-therapy-in-patients-with-an-acute-or-prior-intracerebral-hemorrhage\" class=\"medical medical_review\">&quot;The use of antithrombotic therapy in patients with an acute or prior intracerebral hemorrhage&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Initial management of elevated intracranial pressure (ICP) includes elevating the head of the bed to 30 degrees and use of analgesia and sedation. Suggested intravenous agents for sedation are <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a>, or <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>. Suggested agents for analgesia and antitussive effect are <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> or <a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">alfentanil</a>.<br/><br/>Invasive monitoring and treatment of ICP should be considered for patients with GCS &lt;8 (<a href=\"image.htm?imageKey=NEURO%2F81854\" class=\"graphic graphic_table graphicRef81854 \">table 1</a>), those with clinical evidence of transtentorial herniation, or those with significant IVH or hydrocephalus. More aggressive therapies for reducing elevated ICP include osmotic diuretics (eg, <a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">mannitol</a>), ventricular catheter drainage of cerebrospinal fluid, and neuromuscular blockade (See <a href=\"#H1113247210\" class=\"local\">'Intracranial pressure'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Severe elevations in blood pressure may worsen ICH by representing a continued force for bleeding. <a href=\"topic.htm?path=labetalol-drug-information\" class=\"drug drug_general\">Labetalol</a>, <a href=\"topic.htm?path=nicardipine-drug-information\" class=\"drug drug_general\">nicardipine</a>, <a href=\"topic.htm?path=esmolol-drug-information\" class=\"drug drug_general\">esmolol</a>, <a href=\"topic.htm?path=enalapril-drug-information\" class=\"drug drug_general\">enalapril</a>, <a href=\"topic.htm?path=hydralazine-drug-information\" class=\"drug drug_general\">hydralazine</a>, <a href=\"topic.htm?path=nitroprusside-drug-information\" class=\"drug drug_general\">nitroprusside</a>, and <a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-drug-information\" class=\"drug drug_general\">nitroglycerin</a> are useful intravenous agents for controlling blood pressure. (See <a href=\"#H18\" class=\"local\">'Blood pressure'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients with systolic blood pressure (SBP) &gt;200 mmHg or mean arterial pressure (MAP) &gt;150 mmHg, we suggest aggressive reduction of blood pressure with continuous intravenous infusion of medication accompanied by blood pressure monitoring every five minutes (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients with SBP &gt;180 mmHg or MAP &gt;130 mmHg and evidence or suspicion of elevated ICP, we suggest monitoring ICP and reducing blood pressure using intermittent or continuous intravenous medication to keep cerebral perfusion pressure in the range of 61 to 80 mmHg (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients with SBP &gt;180 mmHg or MAP &gt;130 mmHg and no evidence or suspicion of elevated ICP, we suggest a modest reduction of blood pressure to a target MAP of 110 mmHg or target blood pressure of <span class=\"nowrap\">160/90</span> mmHg using intermittent or continuous intravenous medication accompanied by reexamination of the patient every 15 minutes (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Appropriate intravenous antiepileptic treatment should be used to quickly control seizures for patients with ICH and clinical seizures. (See <a href=\"#H20\" class=\"local\">'Seizure prophylaxis and treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with cerebellar hemorrhages &gt;3 cm in diameter who are deteriorating or who have brainstem compression <span class=\"nowrap\">and/or</span> hydrocephalus due to ventricular obstruction, we recommend surgical removal of hemorrhage (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>).<br/><br/>Surgery for supratentorial ICH is controversial, and current guidelines suggest consideration of standard craniotomy only for those with life-threatening mass effect who have lobar clots within 1 cm of the surface. The routine evacuation of supratentorial ICH is not recommended. (See <a href=\"#H21\" class=\"local\">'Surgery'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recombinant factor VIIa treatment for acute ICH is investigational and should not be used for the treatment of ICH outside the context of a clinical trial. (See <a href=\"#H22\" class=\"local\">'Hemostatic therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The 30-day mortality from intracerebral hemorrhage ICH ranges from 35 to 52 percent. Among survivors, the prognosis for functional recovery depends upon the location of hemorrhage, size of the hematoma, level of consciousness, patient age, and overall medical health and condition. (See <a href=\"#H8754524\" class=\"local\">'Prognosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treating hypertension is the most important step to reduce the risk of ICH, and probably recurrent ICH. Stopping smoking, heavy alcohol use, and cocaine use are also recommended. (See <a href=\"#H26\" class=\"local\">'Secondary prevention'</a> above.)</p><p/><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/1\" class=\"nounderline abstract_t\">Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 2007; 38:2001.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/2\" class=\"nounderline abstract_t\">Manno EM, Atkinson JL, Fulgham JR, Wijdicks EF. Emerging medical and surgical management strategies in the evaluation and treatment of intracerebral hemorrhage. Mayo Clin Proc 2005; 80:420.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/3\" class=\"nounderline abstract_t\">Morgenstern LB, Hemphill JC 3rd, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010; 41:2108.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/4\" class=\"nounderline abstract_t\">Maas MB, Rosenberg NF, Kosteva AR, et al. Surveillance neuroimaging and neurologic examinations affect care for intracerebral hemorrhage. Neurology 2013; 81:107.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/5\" class=\"nounderline abstract_t\">Abid KA, Vail A, Patel HC, et al. Which factors influence decisions to transfer and treat patients with acute intracerebral haemorrhage and which are associated with prognosis? A retrospective cohort study. BMJ Open 2013; 3:e003684.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/6\" class=\"nounderline abstract_t\">Ciccone A, Celani MG, Chiaramonte R, et al. Continuous versus intermittent physiological monitoring for acute stroke. Cochrane Database Syst Rev 2013; :CD008444.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/7\" class=\"nounderline abstract_t\">Langhorne P, Fearon P, Ronning OM, et al. Stroke unit care benefits patients with intracerebral hemorrhage: systematic review and meta-analysis. Stroke 2013; 44:3044.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/8\" class=\"nounderline abstract_t\">Hemphill JC 3rd, Newman J, Zhao S, Johnston SC. Hospital usage of early do-not-resuscitate orders and outcome after intracerebral hemorrhage. Stroke 2004; 35:1130.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/9\" class=\"nounderline abstract_t\">Balami JS, Buchan AM. Complications of intracerebral haemorrhage. Lancet Neurol 2012; 11:101.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/10\" class=\"nounderline abstract_t\">Manno EM. Update on intracerebral hemorrhage. Continuum (Minneap Minn) 2012; 18:598.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/11\" class=\"nounderline abstract_t\">Andrews CM, Jauch EC, Hemphill JC 3rd, et al. Emergency neurological life support: intracerebral hemorrhage. Neurocrit Care 2012; 17 Suppl 1:S37.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/12\" class=\"nounderline abstract_t\">Martin M, Conlon LW. Does platelet transfusion improve outcomes in patients with spontaneous or traumatic intracerebral hemorrhage? Ann Emerg Med 2013; 61:58.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/13\" class=\"nounderline abstract_t\">Ohwaki K, Yano E, Nagashima H, et al. Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke 2004; 35:1364.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/14\" class=\"nounderline abstract_t\">Sakamoto Y, Koga M, Yamagami H, et al. Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the stroke acute management with urgent risk-factor assessment and improvement-intracerebral hemorrhage study. Stroke 2013; 44:1846.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/15\" class=\"nounderline abstract_t\">Menon RS, Burgess RE, Wing JJ, et al. Predictors of highly prevalent brain ischemia in intracerebral hemorrhage. Ann Neurol 2012; 71:199.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/16\" class=\"nounderline abstract_t\">Garg RK, Liebling SM, Maas MB, et al. Blood pressure reduction, decreased diffusion on MRI, and outcomes after intracerebral hemorrhage. Stroke 2012; 43:67.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/17\" class=\"nounderline abstract_t\">Qureshi AI. Significance of lesions with decreased diffusion on MRI in patients with intracerebral hemorrhage. Stroke 2012; 43:6.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/18\" class=\"nounderline abstract_t\">Butcher KS, Jeerakathil T, Hill M, et al. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke 2013; 44:620.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/19\" class=\"nounderline abstract_t\">Gould B, McCourt R, Asdaghi N, et al. Autoregulation of cerebral blood flow is preserved in primary intracerebral hemorrhage. Stroke 2013; 44:1726.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/20\" class=\"nounderline abstract_t\">Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013; 368:2355.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/21\" class=\"nounderline abstract_t\">Anderson CS, Huang Y, Arima H, et al. Effects of early intensive blood pressure-lowering treatment on the growth of hematoma and perihematomal edema in acute intracerebral hemorrhage: the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT). Stroke 2010; 41:307.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/22\" class=\"nounderline abstract_t\">Qureshi AI, Mohammad YM, Yahia AM, et al. A prospective multicenter study to evaluate the feasibility and safety of aggressive antihypertensive treatment in patients with acute intracerebral hemorrhage. J Intensive Care Med 2005; 20:34.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/23\" class=\"nounderline abstract_t\">Qureshi AI, Palesch YY, Martin R, et al. Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study. Arch Neurol 2010; 67:570.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/24\" class=\"nounderline abstract_t\">Kuramatsu JB, Sauer R, Mauer C, et al. Correlation of age and haematoma volume in patients with spontaneous lobar intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 2011; 82:144.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/25\" class=\"nounderline abstract_t\">Naidech AM, Garg RK, Liebling S, et al. Anticonvulsant use and outcomes after intracerebral hemorrhage. Stroke 2009; 40:3810.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/26\" class=\"nounderline abstract_t\">Mess&eacute; SR, Sansing LH, Cucchiara BL, et al. Prophylactic antiepileptic drug use is associated with poor outcome following ICH. Neurocrit Care 2009; 11:38.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/27\" class=\"nounderline abstract_t\">Poungvarin N, Bhoopat W, Viriyavejakul A, et al. Effects of dexamethasone in primary supratentorial intracerebral hemorrhage. N Engl J Med 1987; 316:1229.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/28\" class=\"nounderline abstract_t\">Helbok R, Kurtz P, Schmidt JM, et al. Effect of mannitol on brain metabolism and tissue oxygenation in severe haemorrhagic stroke. J Neurol Neurosurg Psychiatry 2011; 82:378.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/29\" class=\"nounderline abstract_t\">Dorman HR, Sondheimer JH, Cadnapaphornchai P. Mannitol-induced acute renal failure. Medicine (Baltimore) 1990; 69:153.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/30\" class=\"nounderline abstract_t\">Schwab S, Spranger M, Schwarz S, Hacke W. Barbiturate coma in severe hemispheric stroke: useful or obsolete? Neurology 1997; 48:1608.</a></li><li class=\"breakAll\">Neurological and Neurosurgical Intensive Care. Ropper, AH (Ed), Raven Press, New York 1993.</li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/32\" class=\"nounderline abstract_t\">Ott KH, Kase CS, Ojemann RG, Mohr JP. Cerebellar hemorrhage: diagnosis and treatment. A review of 56 cases. Arch Neurol 1974; 31:160.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/33\" class=\"nounderline abstract_t\">Hankey GJ, Hon C. Surgery for primary intracerebral hemorrhage: is it safe and effective? A systematic review of case series and randomized trials. Stroke 1997; 28:2126.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/34\" class=\"nounderline abstract_t\">Batjer HH, Reisch JS, Allen BC, et al. Failure of surgery to improve outcome in hypertensive putaminal hemorrhage. A prospective randomized trial. Arch Neurol 1990; 47:1103.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/35\" class=\"nounderline abstract_t\">Morgenstern LB, Demchuk AM, Kim DH, et al. Rebleeding leads to poor outcome in ultra-early craniotomy for intracerebral hemorrhage. Neurology 2001; 56:1294.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/36\" class=\"nounderline abstract_t\">Minematsu K. Evacuation of intracerebral hematoma is likely to be beneficial. Stroke 2003; 34:1567.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/37\" class=\"nounderline abstract_t\">Hankey GJ. Evacuation of intracerebral hematoma is likely to be beneficial--against. Stroke 2003; 34:1568.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/38\" class=\"nounderline abstract_t\">Donnan GA, Davis SM. Surgery for intracerebral hemorrhage: an evidence-poor zone. Stroke 2003; 34:1569.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/39\" class=\"nounderline abstract_t\">Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005; 365:387.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/40\" class=\"nounderline abstract_t\">Nakano T, Ohkuma H. Surgery versus conservative treatment for intracerebral haemorrhage--is there an end to the long controversy? Lancet 2005; 365:361.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/41\" class=\"nounderline abstract_t\">Gregson BA, Broderick JP, Auer LM, et al. Individual patient data subgroup meta-analysis of surgery for spontaneous supratentorial intracerebral hemorrhage. Stroke 2012; 43:1496.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/42\" class=\"nounderline abstract_t\">Gautschi OP, Schaller K. Surgery or conservative therapy for cerebral haemorrhage? Lancet 2013; 382:377.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/43\" class=\"nounderline abstract_t\">Prasad K, Mendelow AD, Gregson B. Surgery for primary supratentorial intracerebral haemorrhage. Cochrane Database Syst Rev 2008; :CD000200.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/44\" class=\"nounderline abstract_t\">Brown DL, Morgenstern LB. Stopping the bleeding in intracerebral hemorrhage. N Engl J Med 2005; 352:828.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/45\" class=\"nounderline abstract_t\">Broderick JP. The STICH trial: what does it tell us and where do we go from here? Stroke 2005; 36:1619.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/46\" class=\"nounderline abstract_t\">Mendelow AD, Gregson BA, Rowan EN, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet 2013; 382:397.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/47\" class=\"nounderline abstract_t\">Cruz-Flores S. Early surgery and initial conservative therapy did not differ for outcomes in lobar intracerebral hematomas. Ann Intern Med 2013; 159:JC11.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/48\" class=\"nounderline abstract_t\">Al-Shahi Salman R. Haemostatic drug therapies for acute spontaneous intracerebral haemorrhage. Cochrane Database Syst Rev 2009; :CD005951.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/49\" class=\"nounderline abstract_t\">O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295:293.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/50\" class=\"nounderline abstract_t\">Mayer SA, Brun NC, Broderick J, et al. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 2005; 36:74.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/51\" class=\"nounderline abstract_t\">Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352:777.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/52\" class=\"nounderline abstract_t\">Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358:2127.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/53\" class=\"nounderline abstract_t\">Diringer MN, Skolnick BE, Mayer SA, et al. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage. Stroke 2008; 39:850.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/54\" class=\"nounderline abstract_t\">Sugg RM, Gonzales NR, Matherne DE, et al. Myocardial injury in patients with intracerebral hemorrhage treated with recombinant factor VIIa. Neurology 2006; 67:1053.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/55\" class=\"nounderline abstract_t\">Subramaniam S, Demchuk AM, Watson T, et al. Unexpected posthemorrhagic hydrocephalus in patients treated with rFVIIa. Neurology 2006; 67:1096.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/56\" class=\"nounderline abstract_t\">He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998; 280:1930.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/57\" class=\"nounderline abstract_t\">Hart RG, Halperin JL, McBride R, et al. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 2000; 57:326.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/58\" class=\"nounderline abstract_t\">Biffi A, Halpin A, Towfighi A, et al. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology 2010; 75:693.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/59\" class=\"nounderline abstract_t\">Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37:577.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/60\" class=\"nounderline abstract_t\">Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:227.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/61\" class=\"nounderline abstract_t\">Chapman N, Huxley R, Anderson C, et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke 2004; 35:116.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/62\" class=\"nounderline abstract_t\">Kase CS, Kurth T. Prevention of intracerebral hemorrhage recurrence. Continuum (Minneap Minn) 2011; 17:1304.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/63\" class=\"nounderline abstract_t\">Thrift AG, McNeil JJ, Forbes A, Donnan GA. Risk factors for cerebral hemorrhage in the era of well-controlled hypertension. Melbourne Risk Factor Study (MERFS) Group. Stroke 1996; 27:2020.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/64\" class=\"nounderline abstract_t\">Giroud M, Creisson E, Fayolle H, et al. Risk factors for primary cerebral hemorrhage: a population-based study--the Stroke Registry of Dijon. Neuroepidemiology 1995; 14:20.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/65\" class=\"nounderline abstract_t\">Iribarren C, Jacobs DR, Sadler M, et al. Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association confined to elderly men? The Kaiser Permanente Medical Care Program. Stroke 1996; 27:1993.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/66\" class=\"nounderline abstract_t\">Gonz&aacute;lez-Duarte A, Cant&uacute; C, Ru&iacute;z-Sandoval JL, Barinagarrementeria F. Recurrent primary cerebral hemorrhage: frequency, mechanisms, and prognosis. Stroke 1998; 29:1802.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/67\" class=\"nounderline abstract_t\">Segal AZ, Chiu RI, Eggleston-Sexton PM, et al. Low cholesterol as a risk factor for primary intracerebral hemorrhage: A case-control study. Neuroepidemiology 1999; 18:185.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/68\" class=\"nounderline abstract_t\">Yano K, Reed DM, MacLean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 1989; 20:1460.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/69\" class=\"nounderline abstract_t\">Shinkawa A, Ueda K, Hasuo Y, et al. Seasonal variation in stroke incidence in Hisayama, Japan. Stroke 1990; 21:1262.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/70\" class=\"nounderline abstract_t\">Noda H, Iso H, Irie F, et al. Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study. Circulation 2009; 119:2136.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/71\" class=\"nounderline abstract_t\">Wang X, Dong Y, Qi X, et al. Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. Stroke 2013; 44:1833.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/72\" class=\"nounderline abstract_t\">Woo D, Kissela BM, Khoury JC, et al. Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study. Stroke 2004; 35:1360.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/73\" class=\"nounderline abstract_t\">Amarenco P, Labreuche J, Lavall&eacute;e P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004; 35:2902.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/74\" class=\"nounderline abstract_t\">Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/75\" class=\"nounderline abstract_t\">Leker RR, Khoury ST, Rafaeli G, et al. Prior use of statins improves outcome in patients with intracerebral hemorrhage: prospective data from the National Acute Stroke Israeli Surveys (NASIS). Stroke 2009; 40:2581.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/76\" class=\"nounderline abstract_t\">Hackam DG, Austin PC, Huang A, et al. Statins and intracerebral hemorrhage: a retrospective cohort study. Arch Neurol 2012; 69:39.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/77\" class=\"nounderline abstract_t\">Hackam DG, Woodward M, Newby LK, et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation 2011; 124:2233.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/78\" class=\"nounderline abstract_t\">McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke 2012; 43:2149.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/79\" class=\"nounderline abstract_t\">Westover MB, Bianchi MT, Eckman MH, Greenberg SM. Statin use following intracerebral hemorrhage: a decision analysis. Arch Neurol 2011; 68:573.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/80\" class=\"nounderline abstract_t\">Goldstein LB. Statins after intracerebral hemorrhage: to treat or not to treat. Arch Neurol 2011; 68:565.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/81\" class=\"nounderline abstract_t\">Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8:453.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/82\" class=\"nounderline abstract_t\">Anderson CS, Chakera TM, Stewart-Wynne EG, Jamrozik KD. Spectrum of primary intracerebral haemorrhage in Perth, Western Australia, 1989-90: incidence and outcome. J Neurol Neurosurg Psychiatry 1994; 57:936.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/83\" class=\"nounderline abstract_t\">Counsell C, Boonyakarnukul S, Dennis M, et al. Primary intracerebral hemorrhage in the Oxford-shire community Stroke Project. Cerebrovasc Dis 1995; 5:26.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/84\" class=\"nounderline abstract_t\">Broderick JP, Brott TG, Duldner JE, et al. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 1993; 24:987.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/85\" class=\"nounderline abstract_t\">Fogelholm R, Murros K, Rissanen A, Avikainen S. Long term survival after primary intracerebral haemorrhage: a retrospective population based study. J Neurol Neurosurg Psychiatry 2005; 76:1534.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/86\" class=\"nounderline abstract_t\">Flaherty ML, Haverbusch M, Sekar P, et al. Long-term mortality after intracerebral hemorrhage. Neurology 2006; 66:1182.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/87\" class=\"nounderline abstract_t\">Sacco S, Marini C, Toni D, et al. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke 2009; 40:394.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/88\" class=\"nounderline abstract_t\">Zia E, Engstr&ouml;m G, Svensson PJ, et al. Three-year survival and stroke recurrence rates in patients with primary intracerebral hemorrhage. Stroke 2009; 40:3567.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/89\" class=\"nounderline abstract_t\">van Asch CJ, Luitse MJ, Rinkel GJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010; 9:167.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/90\" class=\"nounderline abstract_t\">Gonz&aacute;lez-P&eacute;rez A, Gaist D, Wallander MA, et al. Mortality after hemorrhagic stroke: data from general practice (The Health Improvement Network). Neurology 2013; 81:559.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/91\" class=\"nounderline abstract_t\">Franke CL, van Swieten JC, Algra A, van Gijn J. Prognostic factors in patients with intracerebral haematoma. J Neurol Neurosurg Psychiatry 1992; 55:653.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/92\" class=\"nounderline abstract_t\">Tuhrim S, Dambrosia JM, Price TR, et al. Intracerebral hemorrhage: external validation and extension of a model for prediction of 30-day survival. Ann Neurol 1991; 29:658.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/93\" class=\"nounderline abstract_t\">Stein M, Misselwitz B, Hamann GF, et al. Intracerebral hemorrhage in the very old: future demographic trends of an aging population. Stroke 2012; 43:1126.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/94\" class=\"nounderline abstract_t\">Saloheimo P, Ahonen M, Juvela S, et al. Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke 2006; 37:129.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/95\" class=\"nounderline abstract_t\">van Beijnum J, Lovelock CE, Cordonnier C, et al. Outcome after spontaneous and arteriovenous malformation-related intracerebral haemorrhage: population-based studies. Brain 2009; 132:537.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/96\" class=\"nounderline abstract_t\">Beslow LA, Licht DJ, Smith SE, et al. Predictors of outcome in childhood intracerebral hemorrhage: a prospective consecutive cohort study. Stroke 2010; 41:313.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/97\" class=\"nounderline abstract_t\">Lo WD, Hajek C, Pappa C, et al. Outcomes in children with hemorrhagic stroke. JAMA Neurol 2013; 70:66.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/98\" class=\"nounderline abstract_t\">Saloheimo P, Lapp TM, Juvela S, Hillbom M. The impact of functional status at three months on long-term survival after spontaneous intracerebral hemorrhage. Stroke 2006; 37:487.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/99\" class=\"nounderline abstract_t\">Hansen BM, Nilsson OG, Anderson H, et al. Long term (13 years) prognosis after primary intracerebral haemorrhage: a prospective population based study of long term mortality, prognostic factors and causes of death. J Neurol Neurosurg Psychiatry 2013; 84:1150.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/100\" class=\"nounderline abstract_t\">Jordan LC, Kleinman JT, Hillis AE. Intracerebral hemorrhage volume predicts poor neurologic outcome in children. Stroke 2009; 40:1666.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/101\" class=\"nounderline abstract_t\">Parry-Jones AR, Abid KA, Di Napoli M, et al. Accuracy and clinical usefulness of intracerebral hemorrhage grading scores: a direct comparison in a UK population. Stroke 2013; 44:1840.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/102\" class=\"nounderline abstract_t\">Rodriguez-Luna D, Rubiera M, Ribo M, et al. Ultraearly hematoma growth predicts poor outcome after acute intracerebral hemorrhage. Neurology 2011; 77:1599.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/103\" class=\"nounderline abstract_t\">Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006; 66:1175.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/104\" class=\"nounderline abstract_t\">Dowlatshahi D, Demchuk AM, Flaherty ML, et al. Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes. Neurology 2011; 76:1238.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/105\" class=\"nounderline abstract_t\">Portenoy RK, Lipton RB, Berger AR, et al. Intracerebral haemorrhage: a model for the prediction of outcome. J Neurol Neurosurg Psychiatry 1987; 50:976.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/106\" class=\"nounderline abstract_t\">Young WB, Lee KP, Pessin MS, et al. Prognostic significance of ventricular blood in supratentorial hemorrhage: a volumetric study. Neurology 1990; 40:616.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/107\" class=\"nounderline abstract_t\">Lisk DR, Pasteur W, Rhoades H, et al. Early presentation of hemispheric intracerebral hemorrhage: prediction of outcome and guidelines for treatment allocation. Neurology 1994; 44:133.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/108\" class=\"nounderline abstract_t\">Tuhrim S, Horowitz DR, Sacher M, Godbold JH. Volume of ventricular blood is an important determinant of outcome in supratentorial intracerebral hemorrhage. Crit Care Med 1999; 27:617.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/109\" class=\"nounderline abstract_t\">Hallevi H, Albright KC, Aronowski J, et al. Intraventricular hemorrhage: Anatomic relationships and clinical implications. Neurology 2008; 70:848.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/110\" class=\"nounderline abstract_t\">Staykov D, Volbers B, Wagner I, et al. Prognostic significance of third ventricle blood volume in intracerebral haemorrhage with severe ventricular involvement. J Neurol Neurosurg Psychiatry 2011; 82:1260.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/111\" class=\"nounderline abstract_t\">Maas MB, Nemeth AJ, Rosenberg NF, et al. Subarachnoid extension of primary intracerebral hemorrhage is associated with poor outcomes. Stroke 2013; 44:653.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/112\" class=\"nounderline abstract_t\">Mayer SA, Sacco RL, Shi T, Mohr JP. Neurologic deterioration in noncomatose patients with supratentorial intracerebral hemorrhage. Neurology 1994; 44:1379.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/113\" class=\"nounderline abstract_t\">Leira R, D&aacute;valos A, Silva Y, et al. Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors. Neurology 2004; 63:461.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/114\" class=\"nounderline abstract_t\">Qureshi AI, Safdar K, Weil J, et al. Predictors of early deterioration and mortality in black Americans with spontaneous intracerebral hemorrhage. Stroke 1995; 26:1764.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/115\" class=\"nounderline abstract_t\">Flemming KD, Wijdicks EF, St Louis EK, Li H. Predicting deterioration in patients with lobar haemorrhages. J Neurol Neurosurg Psychiatry 1999; 66:600.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/116\" class=\"nounderline abstract_t\">Arima H, Wang JG, Huang Y, et al. Significance of perihematomal edema in acute intracerebral hemorrhage: the INTERACT trial. Neurology 2009; 73:1963.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/117\" class=\"nounderline abstract_t\">Cucchiara B, Messe S, Sansing L, et al. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke 2008; 39:2993.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/118\" class=\"nounderline abstract_t\">Falcone GJ, Biffi A, Brouwers HB, et al. Predictors of hematoma volume in deep and lobar supratentorial intracerebral hemorrhage. JAMA Neurol 2013; 70:988.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/119\" class=\"nounderline abstract_t\">Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995; 26:1471.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/120\" class=\"nounderline abstract_t\">Rosand J, Eckman MH, Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004; 164:880.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/121\" class=\"nounderline abstract_t\">Dowlatshahi D, Butcher KS, Asdaghi N, et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012; 43:1812.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/122\" class=\"nounderline abstract_t\">Toyoda K, Okada Y, Minematsu K, et al. Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology 2005; 65:1000.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/123\" class=\"nounderline abstract_t\">Naidech AM, Bernstein RA, Levasseur K, et al. Platelet activity and outcome after intracerebral hemorrhage. Ann Neurol 2009; 65:352.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/124\" class=\"nounderline abstract_t\">Naidech AM, Jovanovic B, Liebling S, et al. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke 2009; 40:2398.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/125\" class=\"nounderline abstract_t\">Foerch C, Sitzer M, Steinmetz H, Neumann-Haefelin T. Pretreatment with antiplatelet agents is not independently associated with unfavorable outcome in intracerebral hemorrhage. Stroke 2006; 37:2165.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/126\" class=\"nounderline abstract_t\">Nilsson OG, Lindgren A, Brandt L, S&auml;veland H. Prediction of death in patients with primary intracerebral hemorrhage: a prospective study of a defined population. J Neurosurg 2002; 97:531.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/127\" class=\"nounderline abstract_t\">Flibotte JJ, Hagan N, O'Donnell J, et al. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004; 63:1059.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/128\" class=\"nounderline abstract_t\">Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28:1.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/129\" class=\"nounderline abstract_t\">Sansing LH, Messe SR, Cucchiara BL, et al. Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH. Neurology 2009; 72:1397.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/130\" class=\"nounderline abstract_t\">Thompson BB, B&eacute;jot Y, Caso V, et al. Prior antiplatelet therapy and outcome following intracerebral hemorrhage: a systematic review. Neurology 2010; 75:1333.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/131\" class=\"nounderline abstract_t\">Hemphill JC 3rd, Bonovich DC, Besmertis L, et al. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke 2001; 32:891.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/132\" class=\"nounderline abstract_t\">Cheung RT, Zou LY. Use of the original, modified, or new intracerebral hemorrhage score to predict mortality and morbidity after intracerebral hemorrhage. Stroke 2003; 34:1717.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/133\" class=\"nounderline abstract_t\">Godoy DA, Pi&ntilde;ero G, Di Napoli M. Predicting mortality in spontaneous intracerebral hemorrhage: can modification to original score improve the prediction? Stroke 2006; 37:1038.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/134\" class=\"nounderline abstract_t\">Hemphill JC 3rd, Farrant M, Neill TA Jr. Prospective validation of the ICH Score for 12-month functional outcome. Neurology 2009; 73:1088.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/135\" class=\"nounderline abstract_t\">Muir KW, Weir CJ, Murray GD, et al. Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke 1996; 27:1817.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/136\" class=\"nounderline abstract_t\">Bar B, Hemphill JC 3rd. Charlson comorbidity index adjustment in intracerebral hemorrhage. Stroke 2011; 42:2944.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/137\" class=\"nounderline abstract_t\">Becker KJ, Baxter AB, Cohen WA, et al. Withdrawal of support in intracerebral hemorrhage may lead to self-fulfilling prophecies. Neurology 2001; 56:766.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/138\" class=\"nounderline abstract_t\">Zahuranec DB, Brown DL, Lisabeth LD, et al. Early care limitations independently predict mortality after intracerebral hemorrhage. Neurology 2007; 68:1651.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/139\" class=\"nounderline abstract_t\">Zahuranec DB, Morgenstern LB, S&aacute;nchez BN, et al. Do-not-resuscitate orders and predictive models after intracerebral hemorrhage. Neurology 2010; 75:626.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/140\" class=\"nounderline abstract_t\">Creutzfeldt CJ, Becker KJ, Weinstein JR, et al. Do-not-attempt-resuscitation orders and prognostic models for intraparenchymal hemorrhage. Crit Care Med 2011; 39:158.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/141\" class=\"nounderline abstract_t\">Passero S, Ciacci G, Ulivelli M. The influence of diabetes and hyperglycemia on clinical course after intracerebral hemorrhage. Neurology 2003; 61:1351.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/142\" class=\"nounderline abstract_t\">Fogelholm R, Murros K, Rissanen A, Avikainen S. Admission blood glucose and short term survival in primary intracerebral haemorrhage: a population based study. J Neurol Neurosurg Psychiatry 2005; 76:349.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/143\" class=\"nounderline abstract_t\">Appelboom G, Piazza MA, Hwang BY, et al. Severity of intraventricular extension correlates with level of admission glucose after intracerebral hemorrhage. Stroke 2011; 42:1883.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/144\" class=\"nounderline abstract_t\">B&eacute;jot Y, Aboa-Eboul&eacute; C, Hervieu M, et al. The deleterious effect of admission hyperglycemia on survival and functional outcome in patients with intracerebral hemorrhage. Stroke 2012; 43:243.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/145\" class=\"nounderline abstract_t\">Rodriguez-Luna D, Rubiera M, Ribo M, et al. Serum low-density lipoprotein cholesterol level predicts hematoma growth and clinical outcome after acute intracerebral hemorrhage. Stroke 2011; 42:2447.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/146\" class=\"nounderline abstract_t\">Lee SH, Kim BJ, Ryu WS, et al. White matter lesions and poor outcome after intracerebral hemorrhage: a nationwide cohort study. Neurology 2010; 74:1502.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/147\" class=\"nounderline abstract_t\">Caprio FZ, Maas MB, Rosenberg NF, et al. Leukoaraiosis on magnetic resonance imaging correlates with worse outcomes after spontaneous intracerebral hemorrhage. Stroke 2013; 44:642.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/148\" class=\"nounderline abstract_t\">Di Napoli M, Godoy DA, Campi V, et al. C-reactive protein level measurement improves mortality prediction when added to the spontaneous intracerebral hemorrhage score. Stroke 2011; 42:1230.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/149\" class=\"nounderline abstract_t\">Chen ST, Chiang CY, Hsu CY, et al. Recurrent hypertensive intracerebral hemorrhage. Acta Neurol Scand 1995; 91:128.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/150\" class=\"nounderline abstract_t\">Bae H, Jeong D, Doh J, et al. Recurrence of bleeding in patients with hypertensive intracerebral hemorrhage. Cerebrovasc Dis 1999; 9:102.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/151\" class=\"nounderline abstract_t\">Hanger HC, Wilkinson TJ, Fayez-Iskander N, Sainsbury R. The risk of recurrent stroke after intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 2007; 78:836.</a></li><li><a href=\"https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis/abstract/152\" class=\"nounderline abstract_t\">Huhtakangas J, L&ouml;pp&ouml;nen P, Tetri S, et al. Predictors for recurrent primary intracerebral hemorrhage: a retrospective population-based study. Stroke 2013; 44:585.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 1084 Version 20.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H28\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">INITIAL TREATMENT</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">General management issues</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Reversal of anticoagulation</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Blood pressure</a><ul><li><a href=\"#H8751460\" id=\"outline-link-H8751460\">- Guidelines for treatment</a></li></ul></li><li><a href=\"#H20\" id=\"outline-link-H20\">Seizure prophylaxis and treatment</a></li><li><a href=\"#H1113247210\" id=\"outline-link-H1113247210\">Intracranial pressure</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">Surgery</a><ul><li><a href=\"#H356881360\" id=\"outline-link-H356881360\">- Cerebellar hemorrhage</a></li><li><a href=\"#H356881366\" id=\"outline-link-H356881366\">- Supratentorial hemorrhage</a></li></ul></li><li><a href=\"#H2514292\" id=\"outline-link-H2514292\">Intraventricular hemorrhage</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">Hemostatic therapy</a></li></ul></li><li><a href=\"#H8751556\" id=\"outline-link-H8751556\">SECONDARY TREATMENT ISSUES</a><ul><li><a href=\"#H23\" id=\"outline-link-H23\">Resumption of antiplatelet therapy</a><ul><li><a href=\"#H24\" id=\"outline-link-H24\">- Timing and dose</a></li></ul></li><li><a href=\"#H25\" id=\"outline-link-H25\">Resumption of anticoagulation</a></li><li><a href=\"#H26\" id=\"outline-link-H26\">Secondary prevention</a></li></ul></li><li><a href=\"#H8754524\" id=\"outline-link-H8754524\">PROGNOSIS</a><ul><li><a href=\"#H8754565\" id=\"outline-link-H8754565\">Mortality and functional outcome</a></li><li><a href=\"#H8754571\" id=\"outline-link-H8754571\">Risk factors for poor outcomes</a><ul><li><a href=\"#H8754577\" id=\"outline-link-H8754577\">- Initial ICH volume and level of consciousness</a></li><li><a href=\"#H8754583\" id=\"outline-link-H8754583\">- Hematoma growth and clinical deterioration</a></li><li><a href=\"#H8754589\" id=\"outline-link-H8754589\">- Preceding antithrombotic use</a></li><li><a href=\"#H8754595\" id=\"outline-link-H8754595\">- ICH score</a></li><li><a href=\"#H8754601\" id=\"outline-link-H8754601\">- Other factors</a></li></ul></li><li><a href=\"#H8754607\" id=\"outline-link-H8754607\">Recurrence</a></li></ul></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H27\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H28\" id=\"outline-link-H28\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"NEURO/1084|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=NEURO/81854\" class=\"graphic graphic_table\">- Glasgow Coma Scale (GCS)</a></li><li><a href=\"image.htm?imageKey=NEURO/75411\" class=\"graphic graphic_table\">- Modified Rankin scale</a></li><li><a href=\"image.htm?imageKey=NEURO/61698\" class=\"graphic graphic_table\">- NIH Stroke Scale</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=cerebral-amyloid-angiopathy\" class=\"medical medical_review\">Cerebral amyloid angiopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-and-laboratory-aspects-of-platelet-transfusion-therapy\" class=\"medical medical_review\">Clinical and laboratory aspects of platelet transfusion therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-use-of-neuromuscular-blocking-agents-in-critically-ill-patients\" class=\"medical medical_review\">Clinical use of neuromuscular blocking agents in critically ill patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=complications-of-mannitol-therapy\" class=\"medical medical_review\">Complications of mannitol therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=convulsive-status-epilepticus-in-adults-classification-clinical-features-and-diagnosis\" class=\"medical medical_review\">Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-and-management-of-elevated-intracranial-pressure-in-adults\" class=\"medical medical_review\">Evaluation and management of elevated intracranial pressure in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=heparin-and-lmw-heparin-dosing-and-adverse-effects\" class=\"medical medical_review\">Heparin and LMW heparin: Dosing and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-assessment-and-management-of-acute-stroke\" class=\"medical medical_review\">Initial assessment and management of acute stroke</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-treatment-of-epilepsy-in-adults\" class=\"medical medical_review\">Initial treatment of epilepsy in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intraventricular-hemorrhage\" class=\"medical medical_review\">Intraventricular hemorrhage</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-bleeding-in-patients-receiving-direct-oral-anticoagulants\" class=\"medical medical_review\">Management of bleeding in patients receiving direct oral anticoagulants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=medical-complications-of-stroke\" class=\"medical medical_review\">Medical complications of stroke</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nonconvulsive-status-epilepticus\" class=\"medical medical_review\">Nonconvulsive status epilepticus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hemorrhagic-stroke-the-basics\" class=\"medical medical_basics\">Patient education: Hemorrhagic stroke (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hemorrhagic-stroke-treatment-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Hemorrhagic stroke treatment (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=recombinant-factor-viia-clinical-uses-dosing-and-adverse-effects\" class=\"medical medical_review\">Recombinant factor VIIa: Clinical uses, dosing, and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=reversal-of-anticoagulation-in-warfarin-associated-intracerebral-hemorrhage\" class=\"medical medical_review\">Reversal of anticoagulation in warfarin-associated intracerebral hemorrhage</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sedative-analgesic-medications-in-critically-ill-adults-selection-initiation-maintenance-and-withdrawal\" class=\"medical medical_review\">Sedative-analgesic medications in critically ill adults: Selection, initiation, maintenance, and withdrawal</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=serum-osmolal-gap\" class=\"medical medical_review\">Serum osmolal gap</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=spontaneous-intracerebral-hemorrhage-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-use-of-antithrombotic-therapy-in-patients-with-an-acute-or-prior-intracerebral-hemorrhage\" class=\"medical medical_review\">The use of antithrombotic therapy in patients with an acute or prior intracerebral hemorrhage</a></li></ul></div></div>","javascript":null}